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Background: No devices are currently available in the USA for percutaneous closure
of perimembranous (Pm) ventricular septal defects (VSDs). The earlier device was
withdrawn from clinical trial because of development of heart block possibly related to
over sizing and/or device rigidity. New, softer devices are available for vascular oc-
clusions as the Amplazer Vascular Plug II (AVP II) and the Amplatzer Duct Occluder
II (ADO II). We previously submitted our initial experience in occluding Pm VSDs
using AVP II & ADO II in 10 patients (pts) using AVP II in 6 and ADO II in 4. This is
follow up (f/up) of these pts and additional pt.
Methods: F/up data of these pts. were reviewed speciﬁcally assessing for the devel-
opment of heart block, residual ﬂow through the device, presence of aortic insufﬁciency
(AI) and device embolization or fracture or the occurrence of late adverse events (AE).
Results: Review of F/up data of these pts. was performed speciﬁcally assessing for the
development of heart block, residual ﬂow through the device, presence of aortic
insufﬁciency (AI) and device embolization or fracture or the occurrence of late
adverse events (AE).
Results: F/up clinical evaluations, chest x-rays and echocardiograms were available
for all patients expect 1 who did not undergo chest x ray because of pregnancy. F/up
period ranged from 0-13 months with a median of 5.5 + 5. New AI was seen in 3
patients graded as mild in 1 and trivial in 2. In 1 patient the AI could have been
preexisting and masked by the VSD ﬂow. 1 patient had mild new Tricuspid regur-
gitation. There was no incidence of device fracture or late embolization and no clinical
evidence of hemolysis, sub-acute bacterial endocarditis or any serious AE. No patient
developed heart block. In 1 patient with elongated tunnel type VSD, the device took
the conﬁguration of the defect. 1 patient had residual ﬂow through the device which
disappeared on follow up. I patient has additional small VSD.
Conclusions: In our series, percutaneous closure of PmVSDs using the softer new
generation devices as the AVP II and the ADO II appears to be safe in the short term.
Flow seen through the device usually disappears as the device endothelializes.
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Background: Residual lesions after surgical repair of complex congenital heart dis-
ease (CHD) are poorly tolerated. An exit angiography (EA) after cardiopulmonary
bypass (CPB) has been performed to promptly diagnose residual lesions, which may
result in a change of the management strategy. We report our initial experience with
EA and intraoperative stenting (IOS) in a dedicated hybrid suite (HS).
Methods: Patients (pts) with complex CHD were selected for EA at multidisci-
plinary meetings. All procedures were conducted in a dedicated HS in the OR.
Catheters were advanced through sheaths secured by purse string sutures in the
RVOT, SVC, MPA or ascending aorta. Stent delivery was guided by ﬂuoroscopy
after CPB completion.
Results: From 05/12 to 05/14, EA was performed in 22 pts (median age and weight:
0.9 years and 9.2 kg, respectively) after surgical repair (Glenn operations, uni-
focalization, bioprosthetic valve insertion, complex CoA). Twelve patients (55%)
required IOS with 14 stents implanted in the PAs or descending aorta (1). The decision
to implant a stent was made before hand in 4 pts and only after EA was performed in 8
pts (2 pts had undergone a failed redo surgical PA plasty under CPB after an initial
EA). In all patients, stents were placed in the intended location and resulted in sig-
niﬁcant increase of vessel diameter from a median of 3.7 to 8.5 mm (p< 0.001). There
were no deaths or vascular complications during the procedure. Of those 12 patients
who underwent IOS, 8 pts had an uneventful early postoperative period. Two pts died
in the ICU (1 pt with complex univentricular heart and 1 pt with HLHS in ECMO after
Norwood-Glenn operation) and 1 patient each needed hemodialysis and peri-
cardiocentesis, respectively, not related to EA or IOS. Of those 10 pts in whom IOS
was not performed, surgical results were considered adequate and post-op course was
uneventful.
Conclusions: EA and IOS were feasible, safe and effective. EA should be carefully
planned before surgery in selected patients and may result in changes in management
strategies. IOS probably results in better immediate surgical outcomes.B50 JACC Vol 64/11/Suppl B j SepLeft Atrial Appendage Exclusion
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Background: Transcatheter left atrial appendage occlusion (LAAO) is a promising
therapy for stroke prophylaxis in non-valvular atrial ﬁbrillation (NVAF) but its cost-
effectiveness remains understudied.
Methods: A Markov decision analytic model was used to compare cost-effectiveness
of LAAO with 7 alternative strategies: Aspirin alone, Clopidogrel plus Aspirin,
Warfarin, Dabigatran (110 and 150mg), Apixaban, and Rivaroxaban. This model
simulates a cohort of 65-year-old NVAF patients moving between different health
statuses in each Markov cycle of 1 year. The time horizon was lifetime (85 years old).
Health states include AF without event, with event before, ischemic cerebrovascular
events, hemorrhage, myocardial infarction, vascular or non-vascular deaths. To esti-
mate discounted (3%) lifetime costs, quality-adjusted life years (QALYs) and incre-
mental cost-effectiveness ratios (ICERs). Base-case data were derived from ACTIVE,
RE-LY, PROTECT-AF and PREVAIL trials. One-way sensitivity analysis varied by
HAS-BLED scores and time horizons, and probabilistic sensitivity analysis (PSA)
using Monte Carlo simulations were conducted to assess parameter uncertainty.
Results: Compared with Aspirin alone, Clopidogrel plus Aspirin, Warfarin, Dabigatran
110mg, LAAO was cost-effective with an ICER of $3,921, $2,226, $3431, and $58 per
QALY gained, respectively; however, LAAO was dominant to Dabigatran 150mg,
Apixaban, and Rivaroxaban strategies (i.e. less costly and more effective). Sensitivity
analysis demonstrated signiﬁcant performance in ICERs of LAAO against oral antico-
agulant drugs for patients with increasing HAS-BLED scores and within the varied time
horizons (5, 10, and 15 years), and LAAO strategy was cost-effective over 99% of the
Monte Carlo simulation using a cost-effectiveness threshold of US$50,000/QALY.
Conclusions: Transcatheter LAAO strategy is considered cost-effective as compared
with 7 other antithrombotic strategies for prevention of stroke in patients with NVAF
regardless of their risks of ischemic stroke.
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Background:WATCHMAN left atrial appendage (LAA) closure is a novel approach
to preventing stroke in patients with atrial ﬁbrillation (AF) that could reduce the
longer-term risk of bleeding compared with anticoagulation. We compared the tem-
poral incidence of major bleeding beyond the immediate procedural period in the
randomized trials of the device.
Methods: Landmark analyses of time-to-ﬁrst major bleed in the PROTECT-AF,
PREVAIL, and pooled trials were performed for 3 periods: (1) from 8-to-45 days post-
procedure, during which WATCHMAN patients received warfarin; (2) from 46-to-
180 days, during which WATCHMAN patients received dual antiplatelet therapy
(DAPT); and (3) beyond 180 days, when WATCHMAN patients were eligible to
receive aspirin alone. Major bleeding was site-reported and adjudicated as a serious
adverse event by the Clinical Events Committee.
Results: After the periprocedural period, the risk of major bleeding did not differ
signiﬁcantly between study arms when WATCHMAN patients received warfarin or
DAPT. Beyond 6 months, the bleeding risk was signiﬁcantly lower with the device
strategy compared with long-term warfarin (Hazard Ratio [HR] 0.30 [95% Conﬁdence
Interval (CI): 0.17-0.53), a ﬁnding that was consistent across trials (PROTECT-AF:
HR 0.31 [95% CI: 0.16-0.61]; PREVAIL, HR 0.27 [95% CI: 0.09-0.79]).tember 13–17, 2014 j TCT Abstracts/Left Atrial Appendage Exclusion
